This page documents identified gaps in Parkinson's Disease (PD) content coverage in NeuroWiki as of March 2026.
This page documents identified gaps in Parkinson's Disease (PD) content coverage in NeuroWiki as of March 2026.
Analysis of 293 existing PD-related pages reveals strong coverage of major topics including:
- Core PD genes (SNCA, LRRK2, GBA, PINK1, Parkin, DJ-1)
- Key pathways (mitophagy, autophagy-lysosome, ubiquitin-proteasome)
- Cell types (dopaminergic neurons, microglia, astrocytes)
- Major disease mechanisms (alpha-synuclein aggregation, neuroinflammation)
However, several gaps remain that represent opportunities for content expansion.
| Gene |
Notes |
| OTUD3 (PARK11) |
Deubiquitinase, uncertain pathogenicity |
| DNC1 (PARK19) |
Dynein cytoplasmic 1, recently implicated |
| PARS10 (PARK20) |
Recently identified, limited understanding |
| Variant |
Pathogenicity |
Notes |
| A30P |
Pathogenic |
Early discovered, rapid aggregation |
| E46K |
Pathogenic |
Lewy body dementia link |
- DaTscan (DAT-SPECT): Dopamine transporter imaging - critical for PD differential diagnosis
- Alpha-synuclein PET: Novel tau-style imaging tracers in development
- fMRI protocols: Functional connectivity changes in early PD
- Hyposmia screening: Olfactory dysfunction as early PD marker
- Constipation: Gastrointestinal prodromal marker
- Phase 1 PD trials: List of ongoing Phase 1 trials
- Phase 3 PD trials: List of Phase 3 failures and successes
- Lentiviral gene therapy vectors: Alternative to AAV
| Researcher |
Expertise |
Priority |
| Erwan Bezard |
LRRK2, dopamine biology |
High |
| J. William Langston |
MPTP, alpha-syn discovery |
High |
| C. Warren Olanow |
Basal ganglia, DBS |
High |
| Lorraine V. Kalia |
Translation, clinical |
Medium |
| J. Michael Schulz |
LRRK2 biology |
Medium |
| Birgit H. Walker Wider |
PINK1 |
Medium |
| Antonio M. Valente |
PINK1 |
Medium |
| Michael A. Dawson |
Tau, alpha-syn mechanisms |
High |
| Ted M. Dawson |
Neuroprotection |
High |
| Elena Greggio |
LRRK2 kinase |
Medium |
| Anthony H. V. Schapira |
GBA, clinical |
High |
| Stanley Fahn |
Clinical standards |
Medium |
| Christopher G. Goetz |
Clinical ratings |
Medium |
| Werner Poewe |
Clinical trials |
Medium |
| Paola Piccini |
Neuroimaging |
Medium |
| David J. Brooks |
PET imaging |
Medium |
| Bernard J. Snow |
Clinical trials |
Low |
| Jonathan S. Ravina |
Clinical development |
Medium |
| Pablo Sardi |
GBA, gene therapy |
High |
- Nucleic acid homeostasis: tRNA modifications in PD
- Metallostasis: Iron, copper, zinc dysregulation
- Circadian disruption: CLOCK genes in PD
- Extracellular vesicles: Synuclein spread mechanism
- Bidirectional gut-brain axis: Microbiome connections
- LRRK2 kinase inhibitors: Clinical trial status
- GBA chaperone therapies: Small molecule approaches
- Alpha-synuclein aggregation inhibitors: Current pipeline
- Metabolic modulators: PPAR agonists, mTOR-independent autophagy
- Minor PARK genes: ATP13A9, GIGYF2, DNAJC13, VPS13C - limited depth
- Rare PD subtypes: Multiple system atrophy (MSA), Progressive supranuclear palsy (PSP) - need more content
- Non-motor symptoms: Sleep disorders, autonomic dysfunction, neuropsychiatric symptoms
- Animal models: MPTP, 6-OHDA, alpha-syn transgenic models
- Create SNCA A30P and E46K variant pages
- Add DaTscan and alpha-syn PET imaging pages
- Create top 10 researcher pages (Bezard, Langston, Olanow, Dawson, Dawson, Sardi, Schapira, Kalia, Greggio)
- Add prodromal PD markers (hyposmia, constipation, RBD)
- Expand rare PARK gene pages (OTUD3, DNC1, PARS10)
- Add LRRK2 inhibitor clinical trial page
- Create phase clinical trial index for PD
- Add fMRI protocols in PD
- Historical PD research timeline
- Geographic disease patterns
- PD animal model comparison
- Industry pipeline overview
Last updated: 2026-03-20